Press release
Myelodysplastic Syndrome Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, MOA, ROA and Companies by DelveInsight | Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
Myelodysplastic Syndrome Clinical Trials
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
• The leading companies working in the Myelodysplastic Syndrome Market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Promising Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
• On December 2023, Celgene announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).
• On December 2023, Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
• On December 2023, Celgene announced a study of Phase 1 clinical trials for CC-91633. Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.
Request a sample and discover the recent advances in Myelodysplastic Syndrome Treatment Drugs @ Myelodysplastic Syndrome Pipeline Outlook Report- https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
In the Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Myelodysplastic Syndrome Overview
Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.
Find out more about Myelodysplastic Syndrome Treatment Landscape @ Drugs for Myelodysplastic Syndrome Treatment- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Myelodysplastic Syndrome Emerging Drugs Profile
• MBG453: Novartis
• Tamibarotene: Syros Pharmaceuticals
• CA-4948: Curis
• RVU120: Ryvu Therapeutics
Myelodysplastic Syndrome Pipeline Therapeutics Assessment
There are approx. 120+ key companies which are developing the therapies for Myelodysplastic Syndrome. The Myelodysplastic Syndrome companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.
DelveInsight's Myelodysplastic Syndrome Pipeline Report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Myelodysplastic Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Learn more about the emerging Myelodysplastic Syndrome Pipeline Therapies @ Myelodysplastic Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Myelodysplastic Syndrome Pipeline Report
• Coverage- Global
• Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
• Myelodysplastic Syndrome Pipeline Therapies- Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
Dive deep into rich insights for new drugs for Myelodysplastic Syndrome treatment, Visit @ Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Myelodysplastic Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Myelodysplastic Syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. MBG453: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CA-4948: Curis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. RVU120: Ryvu Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Myelodysplastic Syndrome Key Companies
21. Myelodysplastic Syndrome Key Products
22. Myelodysplastic Syndrome- Unmet Needs
23. Myelodysplastic Syndrome- Market Drivers and Barriers
24. Myelodysplastic Syndrome- Future Perspectives and Conclusion
25. Myelodysplastic Syndrome Analyst Views
26. Myelodysplastic Syndrome Key Companies
27. Appendix
For further information on the Myelodysplastic Syndrome Pipeline Therapeutics, reach out @ Myelodysplastic Syndrome Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelodysplastic Syndrome Clinical Trials Assessment 2024: FDA Approvals, Pipeline, Therapies, MOA, ROA and Companies by DelveInsight | Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others. here
News-ID: 3565927 • Views: …
More Releases from DelveInsight Business Research
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
Narcolepsy Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Update …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Myelodysplastic
Myelodysplastic Syndrome Drugs Market Research and Treatment Advancements
On April 11, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Myelodysplastic Syndrome Drugs Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands…
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.
The myelodysplastic syndrome (MDS)…
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders…
Myelodysplastic Syndrome Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic…
Myelodysplastic Syndrome Market Size, Epidemiology, Analysis & Trends 2023-2033
Market Overview:
The myelodysplastic syndrome market is expected to exhibit a CAGR of 6.51% during 2023-2033. The myelodysplastic syndrome market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the…
Myelodysplastic Syndrome Market to see Huge Growth by 2029
Myelodysplastic Syndrome Market was valued at USD 2.8 billion in 2022 and is expected to grow at a CAGR of 10% between 2023 and 2029. Important changes in the business allow key players to attain larger profits. This Myelodysplastic Syndrome Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry.…
